Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3274486 | Médecine des Maladies Métaboliques | 2012 | 6 Pages |
Abstract
Serological biomarkers i.e. autoantibodies directed to β-cell antigens characterize the ongoing process leading to type 1 diabetes, thus giving the possibility to predict the disease especially in family members of a diabetic proband since sensibility increases with the genetic background. Prevention studies are based upon immunointerventions and the quest for possible induction of immune tolerance. Beta-cell protection and/or regeneration is a key factor of future trials. Modulation of islet autoimmunity in humans after the onset of overt disease can be achieved, and give some reason to be cautiously optimistic for the ability of these and other agents, alone and in combination, to provide an effective immunotherapy for the disease.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
G. Mills-Joncour, C. Thivolet,